The Food and Drug Administration (FDA) has approved Khindivi ™ (hydrocortisone) oral solution as a replacement therapy in ...

Xenoview is a hyperpolarized xenon inhaled contrast agent indicated for use with magnetic resonance imaging for evaluation of lung ventilation.

Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for TransCon ® CNP (navepegritide) for the treatment of children with achondroplasia, a rare ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Direct oral anticoagulants suggested over standard of care anticoagulants for pediatric patients with venous thromboembolism.

Texas, which saw the nation’s largest outbreak during the late winter of 2024 and spring of 2025, reported 10 additional cases this week. The case count in Texas now totals 738.

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

The discovery evidence in this case, particularly the deposition evidence, made it clear that the plaintiff had a strong case against the hospital.

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...